分子影像技术在嵌合抗原受体T细胞疗法中的应用  

Application of molecular imaging in chimeric antigen receptor T cell therapy

作　　者：吴琼 王燕[1] 杨敏[1] Wu Qiong;Wang Yan;Yang Min(NHC Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine,Wuxi 214063,China)

机构地区：[1]国家卫生健康委员会核医学重点实验室、江苏省分子核医学重点实验室、江苏省原子医学研究所,无锡214063

出　　处：《中华核医学与分子影像杂志》2022年第5期308-312,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家重大新药创制项目(2017ZX09304021);江苏省前沿引领技术基础研究计划(BK20192005);江苏省医学创新团队(CXTDA2017024)。

摘　　要：嵌合抗原受体T细胞(CAR-T)疗法是一种新型肿瘤免疫治疗方法,近年来在治疗血液系统肿瘤方面表现出巨大潜力,尤其在治疗复发或难治性急、慢性白血病上已取得突破性进展。目前,CAR-T疗法尚缺乏体内实时监控的有效手段,在治疗血液肿瘤的过程中无法预测及监测治疗效果,从而无法准确预估治疗过程中的并发症和风险,在临床转化过程中面临诸多挑战。分子影像有望用于CAR-T体内生物学行为实时可视化监测,直接标记细胞和报告基因间接评价研究已取得相关突破。该文综述了近年来分子影像技术在CAR-T治疗中的应用并进行展望。Chimeric antigen receptor T cell(CAR-T)therapy,a novel immunotherapy,shows great potential in the treatment of hematological tumors to conventional therapies.Great progress has been made over the past few decades in the treatment of relapsed/refractory acute/chronic lymphocytic leukemia.However,due to the lack of real-time monitoring methods,it is impossible to predict and assess the therapeutic effect during the treatment of blood tumors,and we cannot learn more about the complications and risks.Many challenges exist in the clinical transformation of CAR-T therapy.As a non-invasive method,molecular imaging shows promise on real-time visualization of the biological behavior of CAR-T in vivo.Tracking CAR-T by directly labeling or indirectly evaluation by reporter gene methods has achieved breakthroughs.This article reviews the current situation of monitoring systems of CAR-T therapy and future expectations for each of the methods presented.

关 键 词：免疫疗法 受体 抗原 T细胞 分子成像 发展趋势 

分 类 号：R730.51[医药卫生—肿瘤]